Filing Flows › Ironwood Pharmaceuticals (IRWD) › Q1 2025
Ironwood Pharmaceuticals (IRWD) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Ironwood Pharmaceuticals (IRWD) reported revenue of $41.1M for the first quarter 2025 (Q1 2025), -45% from a year earlier and -55% from the quarter before. Operating margin was -70.7%, net loss $37.4M (90.9% of revenue).
Ironwood Pharmaceuticals, Q1 2025: revenue $41.1M (-45% year over year), operating margin -70.7%, net loss $37.4M, operating cash flow $20.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $41.1M | -55% | -45% |
| Operating profit | −$29.1M | — | — |
| Net earnings | −$37.4M | — | — |
| Operating cash flow | $20.0M | +31% | -56% |
| Free cash flow | $19.9M | +31% | -56% |
What changed
Revenue was $41.1M in Q1 2025, down 45% year over year and down 55% from the previous quarter.
Operating costs exceeded revenue by $29.1M, an operating margin of -70.7%. Total costs grew 10% against a revenue fall of 45%. The fastest-growing cost line was Other operating costs (+4147%). The quarter ended with a net loss of $37.4M, after a profit of $2.3M the previous quarter.
Operating cash flow was $20.0M (down 56% year over year). Non-cash charges added back $479K of depreciation and $5.3M of share-based compensation. Working capital and other items added $51.6M. Capital expenditures of $31K left free cash flow of $19.9M.
Questions
What was Ironwood Pharmaceuticals' revenue in the first quarter 2025?
Ironwood Pharmaceuticals (IRWD) reported revenue of $41.1M for the first quarter 2025 (Q1 2025), -45% from a year earlier and -55% from the quarter before.
Was Ironwood Pharmaceuticals profitable in the first quarter 2025?
Operating loss was $29.1M (-70.7% of revenue) and net loss $37.4M.